Zealand Pharma

697 DKK

-2,31 %

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

Sammenligne

-2,31%

-2,59%

-7,87%

-13,31%

-19,33%

+57,55%

+405,07%

+181,28%

+776,73%

Zealand Pharma er aktiv inden for bioteknologi. Særligt fokus findes på udviklingen af lægemidler til behandling af diabetes og forskellige tarmsygdomme. Virksomheden har en varieret produktportefølje med separate mærker, der sælges på globalt plan. Den største forretning er på det nordiske marked. Zealand Pharma blev grundlagt i 1997 og har hovedkontor i Søborg.

Læs mere

Markedsværdi

49,5 mia. DKK

Aktieomsætning

88,12 mio. DKK

Omsætning

342,79 mio.

EBIT %

-166,94 %

P/E

Udbytteafkast, %

Finanskalender

20.2

2025

Årsrapport '24

8.5

2025

Delårsrapport Q1'25

14.8

2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Pressemeddelelse7.1.2025, 16.00

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma

Pressemeddelelse6.1.2025, 16.00

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Zealand Pharma

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

Video3.1.2025, 16.28 af

Michael Friis, Rasmus Køjborg

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

I denne uges Aktier i Vælten runder vi 2024 af med at se nærmere på hvordan OMXC25, og nogle af de underliggende aktier i indekset har klaret sig i det forgangne år. Samtidig kigger vi ind i hvordan nogle af de indekstunge aktier måske kan udvikle sig i 2025.

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Selskabsmeddelelse25.12.2024, 16.40

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma

Selskabsmeddelelse25.12.2024, 16.30

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Zealand Pharma

Selskabsmeddelelse19.12.2024, 19.58

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Zealand Pharma

Pressemeddelelse10.12.2024, 14.00

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma

Pressemeddelelse13.11.2024, 17.00

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Zealand Pharma

Selskabsmeddelelse11.11.2024, 16.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma

Selskabsmeddelelse7.11.2024, 06.00

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Zealand Pharma

Selskabsmeddelelse8.10.2024, 22.45

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Zealand Pharma

Selskabsmeddelelse8.10.2024, 06.40

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Zealand Pharma

Selskabsmeddelelse30.9.2024, 15.00

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Zealand Pharma

Selskabsmeddelelse30.8.2024, 20.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma

Selskabsmeddelelse30.8.2024, 15.00

Zealand Pharma

697

DKK

-2,31 %

Finanskalender

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

Join Inderes community

Inderes account

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma major shareholder announcement: Bank of America Corporation